Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director · CEO and President | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QUEST DIAGNOSTICS INC
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,423 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 10,000 · Balance 122,423 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 21:05 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 10,000 | $242.72 | $2,427,200.00 |
DisclosureSEC source: 0001599837-26-000007 · wk-form4_1788469527.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,423 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:38 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 10,000 | $194.14 | $1,941,400.00 |
DisclosureSEC source: 0001599837-26-000005 · wk-form4_1780439916.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,423 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 26,414 | $204.86 | $5,411,172.04 |
DisclosureSEC source: 0001022079-26-000028 · wk-form4_1772833455.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,423 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 51,652 | $204.86 | $10,581,428.72 |
DisclosureSEC source: 0001022079-26-000028 · wk-form4_1772833455.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,837 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:38 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 10,000 | $212.52 | $2,125,200.00 |
DisclosureSEC source: 0001022079-26-000021 · wk-form4_1772660306.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,185 F2 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:38 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,968 | $204.86 | $608,024.48 |
DisclosureSEC source: 0001022079-26-000021 · wk-form4_1772660306.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,185 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:11 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 73,225 | $0.00 Strike: $204.96 | $0.00 |
DisclosureSEC source: 0001599837-26-000002 · wk-form4_1771625504.xml · derivative · entry 4 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,225 Underlying: Common Stock · 73,225 shares Expires 2036-02-18 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:11 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,788 | $206.99 | $784,078.12 |
DisclosureSEC source: 0001599837-26-000002 · wk-form4_1771625504.xml · nonDerivative · entry 3 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,153 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:11 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,396 | $210.01 | $503,183.96 |
DisclosureSEC source: 0001599837-26-000002 · wk-form4_1771625504.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,941 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:11 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 15,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001599837-26-000002 · wk-form4_1771625504.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,337 F1 · security: Represents an award of restricted stock units. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 21:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 55,093 | $95.80 Strike: $95.80 | $5,277,633.94 |
DisclosureSEC source: 0001022079-25-000233 · wk-form4_1764365447.xml · derivative · entry 5 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,093 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F5 · derivative.exercise_date: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 21:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 4,747 | $192.97 | $916,036.66 |
DisclosureSEC source: 0001022079-25-000233 · wk-form4_1764365447.xml · nonDerivative · entry 4 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,480 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $192.820 to $193.310. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 21:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 41,004 | $192.27 | $7,883,900.59 |
DisclosureSEC source: 0001022079-25-000233 · wk-form4_1764365447.xml · nonDerivative · entry 3 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,227 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $191.820 to $192.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 21:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 9,342 | $191.59 | $1,789,822.57 |
DisclosureSEC source: 0001022079-25-000233 · wk-form4_1764365447.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,231 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $190.810 to $191.805. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 21:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 55,093 | $95.80 | $5,277,633.94 |
DisclosureSEC source: 0001022079-25-000233 · wk-form4_1764365447.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 7,143 | $175.57 | $1,254,096.51 |
DisclosureSEC source: 0001599837-25-000004 · wk-form4_1762550991.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,480 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 453 | $169.63 | $76,844.20 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 15 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,623 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F16 · price: This transaction was executed in multiple trades at prices ranging from $169.4242 to $169.8209. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 902 | $168.79 | $152,249.48 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 14 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,076 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F15 · price: This transaction was executed in multiple trades at prices ranging from $168.424 to $169.4178. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 1,493 | $167.88 | $250,642.75 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 13 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,978 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F14 · price: This transaction was executed in multiple trades at prices ranging from $167.420 to $168.4134. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 267 | $169.60 | $45,282.45 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 12 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,471 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F13 · price: This transaction was executed in multiple trades at prices ranging from $169.3491 to $169.830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 584 | $168.70 | $98,520.27 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 11 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,738 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F12 · price: This transaction was executed in multiple trades at prices ranging from $168.3348 to $169.3269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 750 | $167.86 | $125,897.10 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 10 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,322 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F11 · price: This transaction was executed in multiple trades at prices ranging from $167.3341 to $168.334. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 2,493 | $169.57 | $422,736.02 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 9 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,072 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F10 · price: This transaction was executed in multiple trades at prices ranging from $169.400 to $169.770. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 5,900 | $168.66 | $995,120.55 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 8 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,565 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F9 · price: This transaction was executed in multiple trades at prices ranging from $168.360 to $169.260. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 6,950 | $167.86 | $1,166,627.00 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 7 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,465 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F8 · price: This transaction was executed in multiple trades at prices ranging from $167.335 to $168.250. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 2,764 | $169.56 | $468,662.46 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 6 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,415 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F7 · price: This transaction was executed in multiple trades at prices ranging from $169.3418 to $169.8434. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 4,905 | $168.72 | $827,563.75 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 5 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,179 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F6 · price: This transaction was executed in multiple trades at prices ranging from $168.3337 to $169.3257. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 7,249 | $167.86 | $1,216,844.69 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 4 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,084 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $167.3326 to $168.3284. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 704 | $169.63 | $119,416.49 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 3 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,333 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $169.570 to $169.750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 1,411 | $168.76 | $238,114.01 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,037 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $168.500 to $169.420. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2025 Filed Apr 5, 2025 00:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 2,366 | $168.03 | $397,553.07 |
DisclosureSEC source: 0001022079-25-000109 · wk-form4_1743812984.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,448 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $167.420 to $168.405. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 31,656 | $173.74 | $5,499,913.44 |
DisclosureSEC source: 0001022079-25-000090 · wk-form4_1741210635.xml · nonDerivative · entry 3 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,814 F3 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock awards. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 61,917 | $173.74 | $10,757,459.58 |
DisclosureSEC source: 0001022079-25-000090 · wk-form4_1741210635.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,470 F2 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock awards approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,662 | $173.74 | $288,755.88 |
DisclosureSEC source: 0001022079-25-000090 · wk-form4_1741210635.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,553 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:38 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,966 | $171.75 | $509,410.50 |
DisclosureSEC source: 0001022079-25-000075 · wk-form4_1740778717.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,215 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,936 | $169.71 | $498,268.56 |
DisclosureSEC source: 0001022079-25-000046 · wk-form4_1740173800.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,181 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 69,633 | $0.00 Strike: $165.30 | $0.00 |
DisclosureSEC source: 0001022079-25-000038 · wk-form4_1739572222.xml · derivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,633 Underlying: Common Stock · 69,633 shares Expires 2035-02-12 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 18,149 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-25-000038 · wk-form4_1739572222.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,117 F1 · security: Represents an award of restricted stock units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,804 | $126.36 | $227,953.44 |
DisclosureSEC source: 0001022079-24-000080 · wk-form4_1709329445.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,968 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,216 | $126.36 | $406,373.76 |
DisclosureSEC source: 0001022079-24-000080 · wk-form4_1709329445.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,772 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 6,525 | $125.02 | $815,755.50 |
DisclosureSEC source: 0001022079-24-000067 · wk-form4_1709069732.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,988 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 13,390 | $125.02 | $1,674,017.80 |
DisclosureSEC source: 0001022079-24-000067 · wk-form4_1709069732.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,513 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2021, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 762 | $125.02 | $95,265.24 |
DisclosureSEC source: 0001022079-24-000054 · wk-form4_1708724127.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,123 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:06 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 92,779 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000036 · wk-form4_1708131954.xml · derivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,779 Underlying: Common Stock · 92,779 shares Expires 2034-02-14 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:06 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 22,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000036 · wk-form4_1708131954.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,885 F1 · security: Represents an award of restricted share units. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 8,036 | $147.86 | $1,188,202.96 |
DisclosureSEC source: 0001022079-23-000065 · wf-form4_167831106431713.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,634 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 15,204 | $147.86 | $2,248,063.44 |
DisclosureSEC source: 0001022079-23-000065 · wf-form4_167831106431713.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,670 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:34 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,292 | $140.69 | $181,771.48 |
DisclosureSEC source: 0001022079-23-000040 · wf-form4_167787924588529.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,466 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:56 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 68,956 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000038 · wf-form4_167753497328240.xml · derivative · entry 3 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,956 Underlying: Common Stock · 68,956 shares Expires 2033-02-23 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:56 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 17,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000038 · wf-form4_167753497328240.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,758 F2 · security: Represents an award of restricted share units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.